Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway
Authors:
- Katsuya ShirakiKSKatsuya Shiraki
- Hiroyuki FukeHFHiroyuki Fuke
- Yutaka YamanakaYYYutaka Yamanaka
- Kazumi MiyashitaKMKazumi Miyashita
- Yumi YamaguchiYYYumi Yamaguchi
- Norihiko YamamotoNYNorihiko Yamamoto
- Keiichi ItoKIKeiichi Ito
- Kazushi SugimotoKSKazushi Sugimoto
- Takeshi NakanoTNTakeshi Nakano
- 1 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 17 (3) , 261-268
Abstract
The ubiquitin–proteasome pathway is responsible for regulating cell cycle proteins, tumor-suppressor molecules, oncogenes, transcription factors, and pro- and anti-apoptotic proteins. The aim of this study is to evaluate the effects of proteasome inhibitors on human hepatocellular carcinoma (HCC) cells. HCC cells SK-Hep1, HLE and HepG2 were treated with the proteasome inhibitors MG132 and MG115. Our data showed that both inhibitors induce apoptosis in the three cell types tested in a dose-dependent manner. Moreover, subtoxic levels of MG132 and MG115 sensitized HCC cells to TRAIL-induced apoptosis. To investigate the mechanism of increased TRAIL sensitivity in HCC cells, we first examined surface expression of TRAIL and its receptors. MG132 upregulated TRAIL and its receptors (TRAIL-R1 and -R2) in SK-Hep1 and HLE, whereas MG115 upregulated them in SK-Hep1. MG132 downregulated expression of X-linked inhibitor of apoptosis protein (XIAP) in SK-Hep1 and HLE, and of survivin in all three cell-types. MG115 downregulated expression of XIAP in SK-Hep1, and survivin in SK-Hep1 and HepG2. Furthermore, MG132 downregulated phospho-AKT and its downstream target phospho-BAD, indicating that MG132 activated the mitochondrial apoptosis pathway by inhibiting phosphorylation of AKT and BAD. In conclusion, proteasome inhibitors induced apoptosis and augmented TRAIL sensitivity via both the IAP family and AKT pathways. Thus, combining proteasome inhibitors with a TRAIL agonist may provide a new therapeutic strategy for HCC.Keywords
This publication has 32 references indexed in Scilit:
- The Ubiquitin-Proteasome Pathway and Its Role in CancerJournal of Clinical Oncology, 2005
- Regulation of apoptosis proteins in cancer cells by ubiquitinOncogene, 2004
- Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cellsOncogene, 2003
- The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cellsOncogene, 2003
- Proteasome-mediated Degradation of Smac during Apoptosis: XIAP Promotes Smac Ubiquitination in VitroJournal of Biological Chemistry, 2002
- Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatinExperimental & Molecular Medicine, 2002
- Deadly encounter: ubiquitin meets apoptosisNature Reviews Molecular Cell Biology, 2002
- Ubiquitin-Proteasome System and Increased Sensitivity of B-CLL Lymphocytes to Apoptotic Death ActivationLeukemia & Lymphoma, 2000
- Lactacystin, a Specific Inhibitor of the Proteasome, Induces Apoptosis in Human Monoblast U937 CellsBiochemical and Biophysical Research Communications, 1995
- Apoptosis in the Pathogenesis and Treatment of DiseaseScience, 1995